메뉴 건너뛰기




Volumn 13, Issue 3, 2011, Pages 179-184

Phase II study of trastuzumab and cisplatin as first-line therapy in patients with HER2-positive advanced gastric or gastroesophageal junction cancer

(13)  Grávalos, Cristina a   Gómez Martín, Carlos a   Rivera, Fernando c   Alés, Inmaculada d   Queralt, Bernardo e   Márquez, Antonia f   Jiménez, Ulpiano g   Alonso, Vicente h   García Carbonero, Rocío i   Sastre, Javier j   Colomer, Ramon k   Cortés Funes, Hernán a   Jimeno, Antonio b  


Author keywords

Adenocarcinoma; Gastric cancer; Gastroesophageal junction; HER2; Phase II; Trastuzumab

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

EID: 79958202400     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-011-0637-6     Document Type: Article
Times cited : (72)

References (26)
  • 1
    • 0037263849 scopus 로고    scopus 로고
    • Gastric cancer epidemiology and risk factors
    • DOI 10.1016/S0895-4356(02)00534-6, PII S0895435602005346
    • Kelley JR, Duggan JM (2003) Gastric cancer epidemiology and risk factors. J Clin Epidemiol 56:1-9 (Pubitemid 36183309)
    • (2003) Journal of Clinical Epidemiology , vol.56 , Issue.1 , pp. 1-9
    • Kelley, J.R.1    Duggan, J.M.2
  • 3
    • 33745547767 scopus 로고    scopus 로고
    • Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data
    • DOI 10.1200/JCO.2005.05.0245
    • Wagner AD, Grothe W, Haerting J et al (2006) Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24:2903-2909 (Pubitemid 46630593)
    • (2006) Journal of Clinical Oncology , vol.24 , Issue.18 , pp. 2903-2909
    • Wagner, A.D.1    Grothe, W.2    Haerting, J.3    Kleber, G.4    Grothey, A.5    Fleig, W.E.6
  • 6
    • 50849105191 scopus 로고    scopus 로고
    • Expression of HER2 in gastric cancer: Comparison between protein expression and gene amplification using a new commercial kit
    • Abstr 4053
    • Yano T, Ochiai A, Doi T et al (2004) Expression of HER2 in gastric cancer: comparison between protein expression and gene amplification using a new commercial kit. J Clin Oncol 22:14S(Abstr 4053)
    • (2004) J Clin Oncol , vol.22
    • Yano, T.1    Ochiai, A.2    Doi, T.3
  • 8
    • 67650395450 scopus 로고    scopus 로고
    • Incidence of gastric or gastro-esophageal cancer in the ToGA trial: Correlation with HER2 positivity
    • abstr 11
    • Kang YK, Bang YJ, Lordick F et al (2008) Incidence of gastric or gastro-esophageal cancer in the ToGA trial: correlation with HER2 positivity. Gastrointestinal Cancers Symposium p. 75 (abstr 11)
    • (2008) Gastrointestinal Cancers Symposium , pp. 75
    • Kang, Y.K.1    Bang, Y.J.2    Lordick, F.3
  • 9
    • 0028907863 scopus 로고
    • Clinical significance of epidermal growth factor (EGF), EGF receptor and c-erbB-2 in human gastric cancer
    • Tokunaga A, Onda M, Okuda T et al (1995) Clinical significance of epidermal growth factor (EGF), EGF receptor and c-erbB-2 in human gastric cancer. Cancer 75:1418-1425
    • (1995) Cancer , vol.75 , pp. 1418-1425
    • Tokunaga, A.1    Onda, M.2    Okuda, T.3
  • 11
    • 0025974889 scopus 로고
    • Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short-term prognosis in gastric cancer
    • Yonemura Y, Ninomiya I, Yamaguchi A et al (1991) Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short-term prognosis in gastric cancer. Cancer Res 51:1034-1038
    • (1991) Cancer Res , vol.51 , pp. 1034-1038
    • Yonemura, Y.1    Ninomiya, I.2    Yamaguchi, A.3
  • 13
    • 50849123421 scopus 로고    scopus 로고
    • HER2 in gastric cancer: A new prognostic factor and a novel therapeutic target
    • Grávalos C, Jimeno A (2008) HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 19:1523-1529
    • (2008) Ann Oncol , vol.19 , pp. 1523-1529
    • Grávalos, C.1    Jimeno, A.2
  • 14
    • 24344489058 scopus 로고    scopus 로고
    • Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model
    • Matsui Y, Inomata M, Tojigamori M et al (2005) Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model. Int J Oncol 27:681-685
    • (2005) Int J Oncol , vol.27 , pp. 681-685
    • Matsui, Y.1    Inomata, M.2    Tojigamori, M.3
  • 16
    • 0024536437 scopus 로고
    • Optimal two-stage designs for phase II clinical trials
    • Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10
    • (1989) Control Clin Trials , vol.10 , pp. 1-10
    • Simon, R.1
  • 20
    • 24944465318 scopus 로고    scopus 로고
    • A multi-institutional phase II randomized trial of docetaxel plus cisplatin (DC) or DC plus 5-fluorouracil (DCF) in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma
    • Ajani JA, Fodor MB, Tjulandin SA et al (2005) A multi-institutional phase II randomized trial of docetaxel plus cisplatin (DC) or DC plus 5-fluorouracil (DCF) in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. J Clin Oncol 23:5660-5667
    • (2005) J Clin Oncol , vol.23 , pp. 5660-5667
    • Ajani, J.A.1    Fodor, M.B.2    Tjulandin, S.A.3
  • 23
    • 14644401104 scopus 로고    scopus 로고
    • Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: Association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate
    • DOI 10.1093/annonc/mdi059
    • Fornier MN, Seidman AD, Schwartz MK et al (2006) Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. Ann Oncol 16:234-239 (Pubitemid 40309302)
    • (2005) Annals of Oncology , vol.16 , Issue.2 , pp. 234-239
    • Fornier, M.N.1    Seidman, A.D.2    Schwartz, M.K.3    Ghani, F.4    Thiel, R.5    Norton, L.6    Hudis, C.7
  • 24
    • 77956262693 scopus 로고    scopus 로고
    • Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial
    • Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687-697
    • (2010) Lancet , vol.376 , Issue.9742 , pp. 687-697
    • Bang, Y.J.1    Van Cutsem, E.2    Feyereislova, A.3
  • 25
    • 67650395446 scopus 로고    scopus 로고
    • Early results of a trial of trastuzumab, cisplatin and docetaxel for the treatment of metastatic gastric cancer overexpressing HER-2
    • abstr 1105
    • Nicholas G, Cripps C, Au H-P et al (2006) Early results of a trial of trastuzumab, cisplatin and docetaxel for the treatment of metastatic gastric cancer overexpressing HER-2. ESMO abstr 1105
    • (2006) ESMO
    • Nicholas, G.1    Cripps, C.2    Au, H.-P.3
  • 26
    • 50849143901 scopus 로고    scopus 로고
    • A pilot study of trastuzumab monotherapy in patients who progressed while on chemotherapy for metastatic or locally advanced HER-2 positive gastric cancer
    • abstr 1096
    • Rech J, Arnold D, Folprecht G et al (2006) A pilot study of trastuzumab monotherapy in patients who progressed while on chemotherapy for metastatic or locally advanced HER-2 positive gastric cancer. ESMO abstr 1096
    • (2006) ESMO
    • Rech, J.1    Arnold, D.2    Folprecht, G.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.